The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

The guidelines include disease-specific recommendations screening, monitoring disease progression, and treatment options for ILD.

Introduction The global bioconjugation market is witnessing robust growth, primarily driven by the expanding demand for targeted therapies and ...